 | |
| Names | |
|---|---|
| IUPAC name 2′,3′-Didehydro-2′,3′-dideoxy-5-fluorocytidine | |
| Systematic IUPAC name 4-Amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-1-yl]pyrimidin-2(1H)-one | |
| Other names Reverset | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider |
|
| KEGG |
|
| UNII | |
| |
| |
| Properties | |
| C9H10FN3O3 | |
| Molar mass | 227.195 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Dexelvucitabine is a failed experimental agent for the management ofhuman immunodeficiency virus infection. It is acytidine nucleoside analog and nucleosidereverse transcriptase inhibitor.[1] that inhibits HIV-1 replication in vitro. Duringphase II clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus.[2][3]
On April 3, 2006,Pharmasset andIncyte, the pharmaceutical companies developing dexelvucitabine, announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia (an excess of the pancreatic enzymelipase in the bloodstream) in a phase II trial.[1][4]
 | Thisantiinfectivedrug article is astub. You can help Wikipedia byexpanding it. |
